Aardvark Therapeutics Is Maintained at Buy by Jones Trading

What happened

Jones Trading maintained a Buy rating on Aardvark Therapeutics but cut its price target to $10.00 per share from $19.00, according to Benzinga ratings actions.

Confirmed

Global impact / market context

A lower price target means the analyst now expects less upside, even while keeping a Buy rating, which means they still see the stock as worth owning. For investors, that gap between the old and new target signals reduced confidence in near-term value.

Analyst inference

The cut almost halves the prior target, from $19.00 to $10.00, a large revision for a maintained Buy. This suggests the analyst re-rated expected returns downward, which can prompt holders to reconsider position sizes and new buyers to demand a wider discount.

Analyst inference

What to watch

1. Watch whether other analysts also cut their price targets for Aardvark Therapeutics after Jones Trading's move to $10.00 from $19.00. Confirmed
2. Watch for any company update on drug development timelines or cash available, since these could explain why the analyst lowered the target while keeping Buy. Proposed
3. Watch trading volume in AARD shares, as a large target cut can shift investor positioning and reveal whether holders are selling or adding. Analyst inference

Evidence

• Original source link unavailable